The implications of the conclusion for the research of miRNA are significant. When the use of miRNA as biomarkers enters the clinical field, the psychological effects on patients will be dramatic because the patients will endure less stress as a result of knowing which cancer is afflicting and whether it will be treatable. Also, they will not be subjected to as many invasive or painful tests. In addition, miRNA plays a role in tumor invasion and metastasis, which means that it can be used to provide a more specific and effective treatment. The discovery of miRNA as a successful biomarker has even led the research into miRNAs as therapeutic targets because of its integration in cancer.  Along with the scientific aspects of miRNA, there are many economic aspects too. Using miRNA as a biomarker will save oncologists from doing many invasive and/or expensive tests to find out if a patient has cancer and what type of cancer because a blood test with a much a cheaper miRNA assay or electrophoresis can be used as a substitute. Another economic benefit to miRNA as a biomarker is that oncologists will be less likely to practice defensive medicine, which includes running unnecessary and often expensive tests to defend themselves against lawsuits, because miRNA is 97.6% accurate for sensitivity as a biomarker for cancer and 96.3% accurate as a biomarker for the classification of cancer.  Thus showing that the discovery of miRNA as a biomarker for cancer is successful because the accuracy is incredibly high, the hope for the patients’ is significant, the process of using miRNA is greatly feasible, and the cost effectiveness is monumental.